Jacob Fleming's 4th Annual Enhancing Clinical Trial Processes

14th-15th May, 2008, Amsterdam
Jacob Fleming's 4th Annual Enhancing Clinical Trial Processes conference will provide the answers to your questions. Industry experts will present real life case studies on different aspects of clinical trials raging from monitoring and site relationship management all through patient recruitment and retention.

Top pharma executives and operational personnel from research and development meet in Amsterdam to share their views and hands-on experiences on up-to date trends for enhancing the process of clinical trials.

Key Speakers:
Assistant VP, Clinical Development, Wyeth, USA
Executive Director Clinical Operations EMEA & APAC, BMS, Belgium
Head of Medical Affairs and Research, Pfizer, India
Head of In- and Outsourcing, Orion Pharma, Finland
Director of Clinical Support, AstraZeneca, Belgium
Clinical Trial Head Nephrology, Novartis, Switzerland

Key topics:
Gain the knowledge on how to increase the productivity and efficiency in monitoring
Discover how to build successful collaboration with investigators
Identify the ways to retain patients in long-term trials
Learn to build a strategy-driven learning and development network organization
Understand how to use flexible outsourcing to its full potentials

Who should attend:
Vice Presidents, Directors, Heads, Senior Managers of Clinical Operations, Clinical Research, Clinical Development, Patients Recruitment Services, Clinical Trials Units, Regulatory Affairs, Contract / Vendor / Outsourcing Management, Project Leaders, Medical Directors, Representatives of patient organizations and CROs

For further information and registration, please visit:
http://www.jacobfleming.com/conferences/life-science/4th-clinical-trials

About Jacob Fleming Group
Jacob Fleming Group is one of the world's leading business intelligence companies producing business-to-business conferences which consists of current research, market trends, technological developments and applications. Our market-led intelligence allows our customers to make informed decisions for maximum bottom-line impact.

Jacob Fleming offices in Bratislava (Slovakia), Prague (Czech republic), Budapest (Hungary), Barcelona (Spain), Dubai (UAE) and Cleveland (USA) specialize in organizing prestigious international conferences for Europe and GCC region, providing groundbreaking strategies and proven technical expertise in both business functional areas and vertical markets through energy, finance, media, pharmaceutical and telecom sectors. For more information, visit www.jacobfleming.com.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...